AMD announced its first life sciences collaboration with AI-based drug developer Absci, providing its hardware and software for Absci’s AI drug discovery. Despite AMD also investing $20m in Absci, its shares fell 4% after HSBC analyst Frank Lee downgraded the firm from “Buy” to “Reduce” and cut its price target by 18%, suggesting AMD will continue trailing market leader Nvidia. This is AMD’s first life-sciences partnership.
China slaps 1-hour deadline on reporting serious cyber incidents
Paul Kunert reports: Beijing will soon expect Chinese network operators to ‘fess up to serious cyber incidents within an hour of spotting them – or
